



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

| APPLICATION NO.   | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO.     |
|---|-------------|----------------------|---------------------|----------------------|
| 09/834,095  | 04/12/2001  | Yoshihiro Kawaoka    | 800.026US1          | 5332                 |
| 21186   | 7590        | 01/08/2004           | EXAMINER            |                      |
| SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.<br>P.O. BOX 2938<br>MINNEAPOLIS, MN 55402 |             |                      |                     | MCKELVEY, TERRY ALAN |
| ART UNIT  |             | PAPER NUMBER         |                     |                      |
|   |             | 1636                 |                     |                      |

DATE MAILED: 01/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

S.M.

|                        |                        |                     |
|------------------------|------------------------|---------------------|
| <b>Advisory Action</b> | <b>Application No.</b> | <b>Applicant(s)</b> |
|                        | 09/834,095             | KAWAOKA, YOSHIHIRO  |
|                        | <b>Examiner</b>        | <b>Art Unit</b>     |
|                        | Terry A. McKelvey      | 1636                |

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 01 December 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

- a)  The period for reply expires 3 months from the mailing date of the final rejection.
- b)  The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  
ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1.  A Notice of Appeal was filed on \_\_\_\_\_. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2.  The proposed amendment(s) will not be entered because:
  - (a)  they raise new issues that would require further consideration and/or search (see NOTE below);
  - (b)  they raise the issue of new matter (see Note below);
  - (c)  they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
  - (d)  they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet.

3.  Applicant's reply has overcome the following rejection(s): \_\_\_\_\_.
4.  Newly proposed or amended claim(s) \_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5.  The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6.  The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7.  For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: \_\_\_\_\_.

Claim(s) objected to: \_\_\_\_\_.

Claim(s) rejected: 1,5,6,9,25,26 and 31.

Claim(s) withdrawn from consideration: 2-4,7,8,10-24 and 27-30.

8.  The drawing correction filed on \_\_\_\_ is a) approved or b) disapproved by the Examiner.

9.  Note the attached Information Disclosure Statement(s) ( PTO-1449) Paper No(s). \_\_\_\_\_.

10.  Other: \_\_\_\_\_.

Continuation of 2. NOTE: For example, the proposed addition of the phrase "in the absence amantadine" to claim 1 is a new limitation not previously examined which raises new issues that would require further consideration and search.

Continuation of 5. does NOT place the application in condition for allowance because: the rejections remain of record due to the non-entry of the proposed amendment. The applicant argues that page 4, lines 15-17 and 27-29 and page 28, lines 22-28 provide support for "wherein the mutation does not alter the in vitro replication of the virus". This argument is not persuasive because as explained in the corresponding rejection of the previous Office Action, page 29, lines 8-9 of the specification contradicts the applicant's cited sections by indicating that there is an effect on amantidine resistance of all M2 mutants (which is an effect on in vitro replication). The applicant's arguments concerning the rejection of the claims under 112, 1st paragraph (starting on page 7 of the Office Action) is drawn to the claims as amended by the proposed amendment and thus are moot due to the non-entry of the proposed amendment.



TERRY MCKELVEY  
PRIMARY EXAMINER